KB-Lanra 1001: A phase 1b/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R/R AML Meeting Abstract
| Authors: | Arnan, M.; Patel, A. A.; Esteve, J.; Morris, L.; Schiller, G. J.; Swords, R. T.; Alonso-Dominguez, J. M.; Michaelis, L. C.; Daver, N.; Carvajal, L. A.; Bray, G.; Olek, E.; Cutler, R. E.; DiMartino, J. F.; Stein, E. M. |
| Abstract Title: | KB-Lanra 1001: A phase 1b/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R/R AML |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 5973 |
| Language: | English |
| ACCESSION: | WOS:001159900803259 |
| DOI: | 10.1182/blood-2023-178804 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
